AN AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE

The hemitartrate salt of a compound represented by the following structural formula: (see above formula) (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	LIU, HANLAN, BHARDWAJ, RENU, MARSHALL, JOHN, COPELAND, DIANE P, PALACE, GERARD, SKELL, JEFFREY, KOCHLING, JIANMEI, SIEGEL, CRAIG, PETERSCHMITT, JUDITH, HARIANAWALA, ABIZER, WILLIS, CHRISTOPHER, CHENG, SENG
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The hemitartrate salt of a compound represented by the following structural formula: (see above formula) (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. Il est décrit le sel dhémitartrate dun composé présenté par la formule structurelle (voir la formule ci-dessus) [Formule 1 Hémitartrate], qui peut servir aux fins dapplications pharmaceutiques. Certaines formes monocristallines de lhémitartrate de la Formule (I) sont caractérisées par une variété de propriétés et de mesures physiques. De plus, on aborde des méthodes de production dhémitartrate de la Formule (I) en forme cristalline et des méthodes selon lesquelles on utiliserait ce dernier pour inhiber la glucosylcéramide synthase et diminuer les concentrations de glycosphingolipide chez les sujets en vue de traiter plusieurs maladies. Des compositions pharmaceutiques sont également décrites.